Alejandro Marinos Velarde, MD
Hematology & Oncology · Dallas, TXNPI 1750722260
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.4%), food and beverage and education — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Incyte Corporation at 49.7% of the total. Reporting peaked in 2024 at $3,878 and has fallen 70.7% since, to $1,134 in 2025.
Across 69 payments — averaging $96.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$3K
- Stemline Therapeutics Inc.$417
- AstraZeneca$306
- Tempus AI, Inc$232
- Sanofi$226
- Rigel Pharmaceuticals, Inc.$200
- plus $2K from 22 others
What the payments were for
- Consulting fees$3,30049%
- Food & beverage$3,26949%
- Education$1112%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 2 | $3,319 |
| Stemline Therapeutics Inc. | 4 | $417 |
| AstraZeneca(2 entities) | 6 | $306 |
| Tempus AI, Inc | 4 | $232 |
| Sanofi | 2 | $226 |
| Rigel Pharmaceuticals, Inc. | 3 | $200 |
| Adaptive Biotechnologies Corporation | 2 | $192 |
| Janssen Scientific Affairs, LLC | 2 | $187 |
| Bristol Myers Squibb | 10 | $173 |
| Agios Pharmaceuticals, Inc. | 4 | $155 |
| E.r. Squibb & Sons, L.L.C. | 2 | $139 |
| Blueprint Medicines Corporation | 1 | $133 |
| AbbVie | 2 | $132 |
| Therakos LLC | 1 | $126 |
| Daiichi Sankyo Inc. | 1 | $125 |
| Sanofi-aventis U.S. LLC | 1 | $122 |
| Jazz Pharmaceuticals Inc. | 2 | $111 |
| Lilly USA, LLC | 5 | $70 |
| Bayer | 4 | $69 |
| Pfizer | 3 | $49 |
| Genetix Biotherapeutics Inc | 1 | $45 |
| Vertex | 1 | $42 |
| Astellas Pharma US Inc | 1 | $22 |
| Novartis | 1 | $21 |
| Amgen | 1 | $19 |
| GSK | 1 | $18 |
| Johnson & Johnson | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,680 in reported general payments places this provider in the 65th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| InqoviDecitabine/Cedazuridine | 15 | $117,937 |
| Posaconazole | 15 | $21,962 |
| Acyclovir | 44 | $583 |
| Levofloxacin | 33 | $553 |
| Prochlorperazine Maleate | 14 | $176 |
| Ondansetron Hcl | 15 | $125 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Dallas
- Edward PearsonDallas$900K
- Christopher MaiselDallas$713K
- Ashwani AgarwalDallas$275K
- Katherine WangDallas$188K
- Houston HolmesDallas$178K
- Benjamin KitchensDallas$177K
- Farrukh AwanDallas$138K
- Dai Chu LuuDallas$90K
- Luis PineiroDallas$86K
- Joan SchillerDallas$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.